OraSure Technologies (OraSure Technologies) Change In Working Capital : $45.8 Mil (TTM As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is OraSure Technologies Change In Working Capital?

OraSure Technologies's change in working capital for the quarter that ended in Dec. 2023 was $10.9 Mil.

OraSure Technologies's change in working capital for the fiscal year that ended in Dec. 2023 was $45.8 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

OraSure Technologies Change In Working Capital Historical Data

The historical data trend for OraSure Technologies's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OraSure Technologies Change In Working Capital Chart

OraSure Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

-8.91

3.96

-31.70

-72.12

45.76

OraSure Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															-35.97	-28.62	51.36	12.12	10.89

OraSure Technologies Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $45.8 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

OraSure Technologies Change In Working Capital Related Terms

Thank you for viewing the detailed overview of OraSure Technologies's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

OraSure Technologies (OraSure Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OraSure Technologies Inc (NAS:OSUR) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

EP3:Germany

Address

220 East First Street, Bethlehem, PA, USA, 18015

Website

https://www.orasure.com

OraSure Technologies is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets most of its sales from the molecular solutions business, derived mainly from customers in the United States.

Executives

Kathleen Gallagher Weber	officer: Chief Product Officer	220 EAST FIRST STREET, BETHLEHEM PA 18017
Michele Marie Miller	officer: VP, Finance and Controller	220 EAST FIRST STREET, BETHLEHEM PA 18017
Robert W. Mcmahon	director	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Kenneth J Mcgrath	officer: Chief Financial Officer	C/O ORASURE TECHNOLOGIES, INC., 220 E. FIRST STREET, BETHLEHEM PA 18015
Ronny B Lancaster	director	ORASURE TECHNOLOGIES INC, 220 EAST FIRST STREET, BETHLEHEM PA 18015
Mara G. Aspinall	director	7381 NORTH MOON SPIRIT LANE, TUCSON AZ 85718
Nancy J Gagliano	director	33 GRANITE WAY, GRANTHAM NH 03753
Michael Celano	director	220 EAST FIRST STREET, BETHLEHEM PA 18015
Manner Carrie Eglinton	director, officer: President & CEO	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Scott Gleason	officer: Interim CFO/SVP IR	1809 SOUTH 2500 EAST, SALT LAKE CITY UT 84108
Eamonn P Hobbs	director	C/O DELCATH SYSTEMS, INC., 600 FIFTH AVENUE, NEW YORK NY 10020
Anne Clem Whitaker	director	109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
James A Datin	director	21 ESTATES DRIVE, DOYLESTOWN PA 18901
Lelio Marmora	director	64 RUE DE VESENEX, DIVONNE LES BAINS I0 01220
Lisa Nibauer	officer: President of Diagnostics	1 CRESENT PLACE, SHORT HILLS NJ 07078